Dengvaxia® is approved for use in several endemic countries in Latin America and Asia where reducing the human and economic burden of dengue is critical.

The vaccine is currently under priority review by the US Food and Drug Administration (FDA) as it would be considered a significant medical advance in the prevention of dengue, which is considered an unmet medical need by the FDA.